FibroGen, Inc. has announced the approval by the China State Administration for Market Regulation for the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited. This approval is a key step in the transaction process, which was initially detailed in a Share Purchase Agreement dated February 20, 2025. The sale is on track to be finalized in the third quarter of 2025, pending the fulfillment of other contractual conditions and deliverables.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9513655-en) on August 18, 2025, and is solely responsible for the information contained therein.